Association between BCL-2 (-938C>A) polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated patients with advanced non-small cell lung cancer

洪卫,林宝钗,张贝贝,余新民,王凯,毛伟敏,张沂平
2014-01-01
Abstract:Objective To investigate the association between BCL- 2 gene polymorphism and therapeutic efficacy of tyro-sine kinase inhibitor(TKI) in pretreated patients with advanced non- smal celllung cancer(NCSLC). Methods A total of 116 pa-tients with advanced NSCLC were recruited from Zhejiang Cancer Hospital, al of whom were treated with gefitinib or erlotinib after failure to chemotherapy. BCL- 2 gene polymorphism of peripheral blood lymphocytes was detected with polymerase chain reac-tion (PCR). Statistical analysis was performed by SPSS version 13.0. Results The overal response rate was 28.9%. No significant association was found between BCL- 2(- 938C>A) polymorphism and the objective response rate. The disease control rate of pa-tients with BCL- 2 AA genotype was lower than that of patients with genotype CC or CA (40%vs 75.2%, P=0.005). Univariate anal-ysis identified gender, smoking history, histology and BCL- 2 (- 938C>A) polymorphism as predictive markers of progress free survival(PFS) (P=0.04, P=0.000, P=0.000 and P=0.05). Multivariate analysis demonstrated that BCL- 2 (- 938C>A) polymorphism was correlated independently with PFS (P=0.049). Conclusion Our data suggest that BCL- 2 (- 938C>A) AA genotype may be a predictive marker for poor DCR and PFS in advanced NSCLC patients treated with tyrosine kinase inhibitor.
What problem does this paper attempt to address?